Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Standard Chartered rises on favourable filing in 'Brutus' case

(Sharecast News) - Standard Chartered shares rose on Friday after the bank welcomed what it described as a favourable filing from the US Department of Justice in a long-running civil case involving allegations of sanctions breaches. The bank said the DoJ's latest position in the so-called 'Brutus' case confirmed that the claims, first brought by a former employee and his associates more than a decade ago, were "false" and repeatedly dismissed by US courts.

Judges previously described the plaintiff's arguments as "on the verge of vexatious and frivolous", "without merit" and falling "far short".

The filing followed years of litigation in which the plaintiffs had sought to revive allegations that Standard Chartered was involved in billions of dollars of unlawful transactions.

The bank has consistently denied the claims, noting that US authorities had already concluded there was no evidence of sanctions violations after a comprehensive investigation.

Shares in the London-headquartered, Asia-focused lender rose 3% after the announcement, partially reversing losses from last week when US Republican lawmaker Elise Stefanik urged the Attorney General to investigate the bank before the case expired.

Standard Chartered said it would continue to cooperate fully with authorities but vowed to defend itself vigorously against "baseless allegations" that it says had been driven by personal financial motives.

At 0927 BST, shares in Standard Chartered weer up 3.27% at 1,404.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.